SCHEMBL6000398

SCHEMBL6000398

Clc1cc(Cl)cc(NCc2ccncc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
GAA P10253 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
PABPC1 P11940 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KDR P35968 3/20 0.47
FLT1 P17948 1/20 0.47
CHEK1 O14757 1/20 0.46
MAP4K4 O95819 1/20 0.46
CHEK2 O96017 1/20 0.46
PRKCG P05129 1/20 0.46
PRKACA P17612 1/20 0.46
RPS6KB1 P23443 1/20 0.46
AKT1 P31749 1/20 0.46
FLT4 P35916 1/20 0.46
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
RPS6KA3 P51812 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000282 0.84 ROCK2 (0.60) ALDH1A1GAAKDM4EMAPTPABPC1
SCHEMBL5999682 0.82 KDR (0.59) ALDH1A1KDM4EMAPTKDRFLT1
SCHEMBL8546536 0.80 HPGD (0.58) ALDH1A1KDM4EMAPTNPSR1L3MBTL1
SCHEMBL19242049 0.79 KDM4E (0.61) ALDH1A1GAAKDM4EMAPTPABPC1
SCHEMBL19241691 0.79 F2 (0.56) ALDH1A1GAAKDM4EMAPTPABPC1
SCHEMBL6000378 0.78 MAPT (0.61) ALDH1A1GAAKDM4EMAPTPABPC1
SCHEMBL26102444 0.77 HTT (0.57) ALDH1A1KDM4EMAPTKDRFLT1
SCHEMBL26485880 0.75 LMNA (0.76) ALDH1A1MAPTNPSR1HPGDMEN1
SCHEMBL19242051 0.74 F2 (0.61) ALDH1A1GAAKDM4EMAPTPABPC1
SCHEMBL522061 0.74 KCNH3 (0.68) CYP1A2CYP2C9CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C ALDH1A1 1891/4885GAA 4852/4885KDM4E 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.